Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC

25 Jul 2022

Abstract excerpt

INTRODUCTION: Echinoderm microtubule-associated protein-like 4 (EML4)-Anaplastic Lymphoma Kinase (ALK) rearrangements occur in 3% to 7% of lung adenocarcinomas and are targets for treatment with tyrosine kinase inhibitors (TKIs). Here we have developed three novel EML4-ALK-positive patient-derived Non-Small-Cell-Lung-Cancer (NSCLC) cancer cell lines, CUTO8 (variant 1), CUTO9 (variant 1) and CUTO29 (variant 3) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35933914
DOI: 10.1016/j.lungcan.2022.07.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLCPMID 35933914Read ↗

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.Semantic proximity Read ↗

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.Semantic proximity Read ↗

EML4‑ALK fusion gene in non‑small cell lung cancer (Review)Semantic proximity Read ↗

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.Semantic proximity Read ↗

NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected PatientsSemantic proximity Read ↗

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsSemantic proximity Read ↗

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

The biology and treatment of EML4-ALK non-small cell lung cancer.Semantic proximity Read ↗

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasisSemantic proximity Read ↗

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.